Healthcare
Corbus Pharmaceuticals Holdings Inc(CRBP)
Live Price
Offline$7.78
+1.04% today
1Y Change
-2.42%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $130.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -60.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Corbus Pharmaceuticals Holdings Inc (CRBP) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $7.78 and down 2.4% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -60.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -60.3%, free cash flow -54.3% with operating margin 0.0% and ROIC -57.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CRBP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -60.3%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +2.3% | +7.1% | -30.8% |
2026 Mar 9, 2026 | +29.8% | +5.1% | -0.4% | +1.7% |
2025 Nov 12, 2025 | -5.6% | -1.1% | +5.6% | -13.5% |
Benchmark Edge
CRBP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CRBP
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CRBP Max Drawdown
-61.88%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CRBP and SPY.
Company Overview
Corbus Pharmaceuticals Holdings Inc
NASDAQ
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for oncology and obesity. The company advances a pipeline of targeted treatments, including CRB-701, a next-generation antibody drug conjugate that targets Nectin-4 expression on cancer cells to deliver a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody designed to block TGFฮฒ activation on cancer cells; and CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist aimed at obesity treatment. These candidates focus on well-understood biological pathways to address serious unmet medical needs in cancer care and weight management. Corbus Pharmaceuticals Holdings, Inc. conducts rigorous clinical trials to evaluate safety, tolerability, and efficacy, with programs in advanced stages for solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and bladder cancer, as well as obesity studies showing promising early weight loss data. Headquartered in Norwood, Massachusetts, the company operates in the high-stakes biopharma sector, emphasizing precision medicine to improve patient outcomes in critical therapeutic areas.
- Leadership
- Dr. Yuval Cohen Ph.D.
- Employees
- 28
- Street Address
- 500 River Ridge Drive
- Mailing
- Norwood, MA, 02062
- Region
- Norwood, MA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.0
Growth
- Revenue
- 0.0%
- EPS
- -60.3%
- Free Cash Flow
- -54.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -65.8%
- ROIC
- -57.2%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 8.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.